Moderna Opens Its First Commercial Office in Europe
In part to increase the potential market reach of its COVID-19 vaccine candidate, Moderna (NASDAQ: MRNA) is opening its first commercial hub outside the United States. The new operation will be in Switzerland, where the company is already working with Swiss drug manufacturer Lonza.
Moderna is using its messenger-RNA (mRNA) platform to develop its candidate, mRNA-1273, which is designed to leverage the body's own genetic messengers to signal it to create antibodies against the novel coronavirus, providing those inoculated with some protection from infection.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
